Issue 3/2011
Content (25 Articles)
Epilepsy in the cancer patient
Odysseas Kargiotis, Sofia Markoula, Athanasios P. Kyritsis
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination
Ramesh K. Ramanathan, James Abbruzzese, Tomislav Dragovich, Lynn Kirkpatrick, Jose M. Guillen, Amanda F. Baker, Linda A. Pestano, Sylvan Green, Daniel D. Von Hoff
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas
Marisa E. Hill, Xiaobai Li, Sharon Kim, Angela Campbell, Kristy Culler, Mark Bloomston, Mark Zalupski, Gwen Hejna, Tanios Bekaii-Saab
Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas
David Goldstein, M. Corona Gainford, Chris Brown, Niall Tebbutt, Stephen P. Ackland, Guy van Hazel, Michael Jefford, Ehtesham Abdi, Sid Selva-Nayagam, Val Gebski, Danielle Miller, Jenny Shannon
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
Jin Young Kim, Young Rok Do, Keon Uk Park, Jong Gwang Kim, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Hun Mo Ryoo, Sung Hwa Bae, Jin Ho Baek, Hong Suk Song
Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
Noriyuki Masuda, Shunichi Negoro, Frederick Hausheer, Kazuhiko Nakagawa, Kaoru Matsui, Shinzoh Kudoh, Koji Takeda, Nobuyuki Yamamoto, Naruo Yoshimura, Yasuo Ohashi, Masahiro Fukuoka
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice
Yongchuan Gu, Christopher P. Guise, Kashyap Patel, Maria R. Abbattista, Jie Lie, Xueying Sun, Graham J. Atwell, Maruta Boyd, Adam V. Patterson, William R. Wilson
The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid
Antonello A. Romani, Silvia Desenzani, Marina M. Morganti, Maria Cristina Baroni, Angelo F. Borghetti, Paolo Soliani
In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents
Andrew M. Gravett, Wai M. Liu, Sanjeev Krishna, Wing-Chi Chan, Richard K. Haynes, Natalie L. Wilson, Angus G. Dalgleish
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
Eric H. Kraut, Christopher Rhoades, Yilong Zhang, Hao Cheng, Josephine Aimiumu, Ping Chen, James Lang, Donn C. Young, Amit Agrawal, Janet Dancey, Kenneth K. Chan, Michael R. Grever
Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC)
Tetsuya Hamaguchi, Kuniaki Shirao, Yoshihiro Moriya, Shigeaki Yoshida, Susumu Kodaira, Yasuo Ohashi
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect
Saik Urien, François Doz, Carole Giraud, Elisabeth Rey, Jean-Claude Gentet, Pascal Chastagner, Gilles Vassal, Nadège Corradini, Anne Auvrignon, Pierre Leblond, Hervé Rubie, Jean-Marc Treluyer
Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo
Meng Liu, Xiao-Juan Luo, Fei Liao, Xiao-Fei Lei, Wei-Guo Dong
Plasma disposition of capecitabine and its metabolites 5′DFCR and 5′DFUR in a standard and dose-intensified monotherapy regimen
Martin Czejka, J. Schueller, A. Farkouh, B. Gruenberger, W. Scheithauer
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas
Weijing Sun, James M. Metz, Maryann Gallagher, Peter J. O’Dwyer, Bruce Giantonio, Richard Whittington, Daniel G. Haller
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases
Tatsuro Yamaguchi, Hiroshi Matsumoto, Michiya Yasutome, Takeo Mori, Keiichi Takahashi
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines
Hua Cheng, She-Juan An, Xu-Chao Zhang, Song Dong, Yi-Fang Zhang, Zhi-Hong Chen, Hua-Jun Chen, Ai-Lin Guo, Qiu-xiong Lin, Yi-Long Wu
Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs
Dirk Heshe, Stephanie Hoogestraat, Christine Brauckmann, Uwe Karst, Joachim Boos, Claudia Lanvers-Kaminsky
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
A. I. Daud, C. Xu, W.-J. Hwu, P. Urbas, S. Andrews, N. E. Papadopoulos, L. C. Floren, A. Yver, R. C. DeConti, V. K. Sondak
Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists
N. Percie du Sert, J. A. Rudd, C. C. Apfel, P. L. R. Andrews
Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines
Patrizia Vici, Alessandra Fabi, Giulio Metro, Domenico Sergi, Diana Giannarelli, Luigi Di Lauro, Gerold Bepler, Federica Tomao, Francesco Cognetti, Francesca Conti, Massimo Lopez
Marginal increase of sunitinib exposure by grapefruit juice
Nielka P. van Erp, Sharyn D. Baker, Anthe S. Zandvliet, Bart A. Ploeger, Margaret den Hollander, Zhaoyuan Chen, Jan den Hartigh, Jacqueline M. C. König-Quartel, Henk-Jan Guchelaar, Hans Gelderblom
Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA)
Hirak S. Basu, Amy Mahlum, Farideh Mehraein-Ghomi, Stacy J. Kegel, Song Guo, Noel R. Peters, George Wilding
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients
Satoshi Yoda, Kenzo Soejima, Hiroyuki Yasuda, Katsuhiko Naoki, Ichiro Kawada, Hideo Watanabe, Ichiro Nakachi, Ryosuke Satomi, Sohei Nakayama, Sinnosuke Ikemura, Hideki Terai, Takashi Sato, Maiko Morosawa, Koichiro Asano
Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization
Emiliano S. Lopez, Manglio M. Rizzo, J. Oscar Croxatto, Guillermo Mazzolini, Juan E. Gallo